Site icon pharmaceutical daily

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026: Triple Therapies will Drive Modest Growth of the COPD Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive dyspnea (shortness of breath) is a key symptom, patients may also present with productive cough. Significant exposure to noxious particles or gases, namely tobacco smoke, is the primary cause of the underlying alveolar and airway abnormalities that result in the airflow limitation and respiratory symptoms that characterize the disease. However, other environmental and occupational exposures or genetic abnormalities may also contribute to symptoms.

Latest Key Takeaways

Key Topics Covered:

OVERVIEW

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

CLINICAL TRIAL LANDSCAPE

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

KEY UPCOMING EVENTS

UNMET NEEDS

BIBLIOGRAPHY

APPENDIX

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f6gx05

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version